MX2016002580A - Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. - Google Patents

Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.

Info

Publication number
MX2016002580A
MX2016002580A MX2016002580A MX2016002580A MX2016002580A MX 2016002580 A MX2016002580 A MX 2016002580A MX 2016002580 A MX2016002580 A MX 2016002580A MX 2016002580 A MX2016002580 A MX 2016002580A MX 2016002580 A MX2016002580 A MX 2016002580A
Authority
MX
Mexico
Prior art keywords
inhibitor
combination
treatment
proliferative diseases
cell proliferative
Prior art date
Application number
MX2016002580A
Other languages
English (en)
Inventor
Leslie Harris Jennifer
Li Nanxin
R Smith Timothy
MOSSE Yael
Wood Andrew
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016002580A publication Critical patent/MX2016002580A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se refiere a una combinación farmacéutica que comprende, separadamente o en conjunto (1) un primer agente el cual es un inhibidor de ALK o una sal farmacéuticamente aceptable del mismo y (2) un segundo agente el cual es un inhibidor de CDK o una sal farmacéuticamente aceptable del mismo. La invención se refiere adicionalmente a al uso de tal combinación en el tratamiento o prevención de enfermedades proliferativas.
MX2016002580A 2013-08-28 2014-08-28 Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas. MX2016002580A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361871275P 2013-08-28 2013-08-28
PCT/US2014/053244 WO2015031666A1 (en) 2013-08-28 2014-08-28 Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases

Publications (1)

Publication Number Publication Date
MX2016002580A true MX2016002580A (es) 2016-10-26

Family

ID=51541330

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002580A MX2016002580A (es) 2013-08-28 2014-08-28 Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.

Country Status (12)

Country Link
US (2) US20160361314A1 (es)
EP (1) EP3038652B1 (es)
JP (1) JP6479812B2 (es)
KR (1) KR20160047521A (es)
CN (1) CN106029099A (es)
AU (3) AU2014312261A1 (es)
BR (1) BR112016004358A8 (es)
CA (1) CA2922684A1 (es)
ES (1) ES2674361T3 (es)
MX (1) MX2016002580A (es)
RU (1) RU2016110874A (es)
WO (1) WO2015031666A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016167511A2 (ko) * 2015-04-14 2016-10-20 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
KR101772134B1 (ko) 2015-04-14 2017-08-29 한국화학연구원 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US11208630B2 (en) * 2015-12-24 2021-12-28 University Of Florida Research Foundation, Incorporated AAV production using suspension adapted cells
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
AU2019205821A1 (en) 2018-01-08 2020-07-09 G1 Therapeutics, Inc. G1T38 superior dosage regimes
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
TW202131917A (zh) 2019-11-18 2021-09-01 日商中外製藥股份有限公司 併用醫藥
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021176349A1 (en) * 2020-03-05 2021-09-10 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
US20230381176A1 (en) * 2020-09-25 2023-11-30 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical composition and use thereof for treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103641833A (zh) * 2006-12-08 2014-03-19 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
EA019941B1 (ru) * 2006-12-08 2014-07-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
PL2331547T3 (pl) * 2008-08-22 2015-01-30 Novartis Ag Związki pirolopirymidynowe jako inhibitory CDK
EP3025724B1 (en) * 2009-05-13 2018-07-11 The University of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
KR101830455B1 (ko) * 2010-04-13 2018-02-20 노파르티스 아게 시클린 의존성 키나제 ４ 또는 시클린 의존성 키나제 （ｃｄｋ４／６） 억제제 및 ｍｔｏｒ 억제제를 포함하는 암 치료를 위한 조합물
RS54189B1 (en) * 2011-02-02 2015-12-31 Novartis Ag PROCEDURES FOR USING ALK INIBITORS

Also Published As

Publication number Publication date
WO2015031666A1 (en) 2015-03-05
CN106029099A (zh) 2016-10-12
EP3038652A1 (en) 2016-07-06
RU2016110874A3 (es) 2018-06-27
KR20160047521A (ko) 2016-05-02
AU2018236813A1 (en) 2018-10-18
RU2016110874A (ru) 2017-10-04
JP6479812B2 (ja) 2019-03-06
US20160361314A1 (en) 2016-12-15
ES2674361T3 (es) 2018-06-29
US20180318305A1 (en) 2018-11-08
AU2014312261A1 (en) 2016-03-10
EP3038652B1 (en) 2018-03-21
CA2922684A1 (en) 2015-03-05
BR112016004358A8 (pt) 2020-02-11
AU2017219093A1 (en) 2017-09-14
JP2016529285A (ja) 2016-09-23

Similar Documents

Publication Publication Date Title
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
PH12018502251A1 (en) Formulations of an lsd1 inhibitor
PH12016502355A1 (en) Pharmaceutical composition
PH12016500871A1 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
MX2020002150A (es) Terapia de combinación para el tratamiento del cáncer.
IN2015DN01156A (es)
MX2015017964A (es) Inhibidores de bromodominio.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2015010829A (es) Compuestos terapeuticos y sus usos.
PH12016502352A1 (en) Pharmaceutical composition
PH12016502353A1 (en) Pharmaceutical composition
IN2014MN02236A (es)
IN2013MU03583A (es)
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
MX2017001461A (es) Terapia de combinacion.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.